Tag: US FDA

  • These Cannabis Stocks Could See Higher Highs

    These Cannabis Stocks Could See Higher Highs

    Cannabis stocks could see higher highs. “Marijuana should be rescheduled as a Schedule III drug as the plant does appear to have medical uses and is less dangerous than other drugs, according to a just made public HHS document,” as noted by Seeking Alpha. “Addressing a 252-page review, HHS Assistant Secretary for Health Rachel Levine wrote…

  • How to Trade the Gene Editing Excitement

    How to Trade the Gene Editing Excitement

    By now, you’ve heard about gene editing. Or, the ability to alter, remove, and even add a DNA sequence to help treat countless disorders we never thought treatable. At the moment, there are about 7,000 diseases caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount…

  • Eli Lilly Could Soon See US FDA Approval for Obesity Drug

    Eli Lilly Could Soon See US FDA Approval for Obesity Drug

    Eli Lilly (LLY) could see higher highs. All as new obesity drug trial results set it up for potential US FDA approval. In fact, in recent trials, patients with Type 2 diabetes lost 15.7% of their body weight within 72 weeks, according to the company. In addition, Eli Lilly noted that “The study met both…

  • This Could be a Mega-Blockbuster for Eli Lilly

    This Could be a Mega-Blockbuster for Eli Lilly

    The obesity epidemic is still bursting at the seams. At the moment, 1.9 billion people are overweight, with more than 650 million considered obese.  In addition, by 2022, $245 billion will be spent on products and services battling the issue.  However, there may be some good news for those looking to shed extra weight. The…

  • Altria Group Stock: Crisis May be Opportunity

    Altria Group Stock: Crisis May be Opportunity

    Keep an eye on Altria Group (MO). For one, the stock is brutally oversold on RSI, MACD, and Williams’ %R.  It’s also oversold at double bottom support dating back to December 2021.  All after the US FDA banned all of Juul Labs’ vape products from the U.S. In fact, the agency noted: “The U.S. Food…

  • The Top Ways to Trade the Coming Psychedelics Boom

    The Top Ways to Trade the Coming Psychedelics Boom

    Psychedelics are going mainstream. For one, the Director of the National Institutes of Health (NIH), Francis Collins recently touted the benefits of psilocybin and MDMA, as noted by Marijuana Moment. “There has been a resurgence of interest in psychedelic drugs, which for a while were sort of considered not an area that researchers legitimately ought…

  • This is Why Mind Med is Attractive Long-Term

    This is Why Mind Med is Attractive Long-Term

    Psychedelic stocks, like Mind Med (MNMD) could see higher highs. All as such treatments show progress in the treatment of depression, anxiety, OCD, ADHD addiction, and post-traumatic stress disorder. In fact, “Researchers at Johns Hopkins and NYU conducted multiple small studies of cancer patientswho experienced anxiety and depression as a result of their diagnoses. After giving these patients psilocybin,…

  • Investors May Want to Use ACADIA Weakness as Opportunity

    Investors May Want to Use ACADIA Weakness as Opportunity

    Don’t write off ACADIA Pharmaceuticals (ACAD) just yet. In early March, the stock gapped from about $45.50 to $20.63.  All after the US FDA rejected its drug to treat hallucinations and delusions associated with dementia-related psychosis (DRP), as noted by the company. “Despite prior agreements with the Division of Psychiatry regarding the pivotal Phase 3 HARMONY study…

  • This is Why All Eyes are on Second Sight Medical Today

    This is Why All Eyes are on Second Sight Medical Today

    There’s a good deal of momentum with Second Sight Medical Products (EYES). Over the last few days, all eyes were on EYES, as it exploded from a low of $1.40 to $14.83.  Volume is now up to 160 million, as compared to daily average volume of 14.3 million.  All on news the US FDA approved…

  • Johnson & Johnson (JNJ) May Be Ready to Rebound

    Johnson & Johnson (JNJ) May Be Ready to Rebound

    Keep an eye on Johnson & Johnson (JNJ). After pulling back from a high of $173.65, it caught support at $161.99.  From here, the stock could again test prior highs if the US FDA grants emergency authorization for its vaccine. With a 66% effective rate in protecting against the virus, JNJ applied for emergency use.…